Immunisation of premature infants

Archives of Disease in Childhood

Volumn 91, Issue 11, 2006, Pages 929-935

  Bonhoeffer, J ^b   Siegrist, C A ^c   Heath, Paul T ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; DIPHTHERIA TETANUS WHOLE CELL PERTUSSIS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MATERNAL ANTIBODY; MEASLES MUMPS VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; STEROID; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; APNEA; B LYMPHOCYTE; BACTERIAL INFECTION; BRADYCARDIA; CARDIOPULMONARY INSUFFICIENCY; DRUG SAFETY; FATTY ACID DESATURATION; GESTATIONAL AGE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LUNG DISEASE; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; VACCINATION;

CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE;

EID: 33750629937     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2005.086306     Document Type: Review

References (81)

1. Davis RL, Rubanowice D, Shinefield MR, et al. Immunization levels among premature and low-birth-weight infants and risk factors for delayed up-to-date immunization status. Centers for Disease Control and Prevention Vaccine Safety Datalink Group. JAMA 1999;282:547-53.
2. Slack MH, Thwaites RJ. Timing of immunisation of premature infants on the neonatal unit and after discharge to the community. Commun Dis Public Health 2000;3:303-4.
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91.
4. Langkamp DL, Davis JP. Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight children. J Pediatr 1996;128:654-9.
5. Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 2002;21:182-6.
6. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54:1-40.
7. Andersson U, Bird G, Britton S. A sequential study of human B lymphocyte function from birth to two years of age. Acta Paediatr Scand 1981;70:837-42.
8. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in tfie United kingdom. J Infect Dis 2002;186:1353-7.
9. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999;179:1569-72.
10. MacLennan JM, Shockley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000;283:2795-801.
11. Rijkers GT, Sanders EA, Breukels MA, et al. Infant B cell responses to polysaccharide determinants. Vaccine 1998;16:1396-400.
12. Madore DV, Johnson CL, Phipps DC, et al. Safety and immunogenicity of Maemophilus influenzas type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months. Pediatrics 1990;86:527-34.
13. Einhorn MS, Weinberg GA, Anderson EL, et al. Immunogenicity in infants of Haemophilus influenza type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 1986;2:299-302.
14. Begg NT, Miller E, Fairley CK, et al. Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection. Vaccine 1995;13:1547-50.
15. Gans HA, Arvin AM, Galinus J, et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998;280:527-32.
16. Goldfarb J, Baley J, Medendorp SV, et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994;13:18-22.
17. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8.
18. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821-9.
19. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520-7.
20. Heath PT, Booy R, McVernon J, et al. Hib vaccination in infants born prematurely. Arch Dis Child 2003;88:206-10.
21. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7.
22. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998;177:1112-15.
23. Kurikka S, Kayhty H, Peltola H, et al. Neonatal immunization: response to Haemophilus influenzae type b tetanus toxoid conjugate vaccine. Pediatrics 1995;95:815-22.
24. Kayhty M, Eskola J, Peltola H, et al. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines. J Infect Dis 1992;165(Suppl 1):S165-6.
25. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003;21:3406-12.
26. Cutts FT, Nyandu B, Markowitz LE, et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine 1994;12:1311-16.
27. Marchant A, Goetghebuer T, Ota MO, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol 1999;163:2249-55.
28. Juhela S, Hyoty H, Lonnrot M, et al. Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol 1998;54:226-32.
29. Sedaghatian MR, Kardouni K. Tuberculin response in preterm infants after BCG vaccination at birth. Arch Dis Child 1993;69:309-11.
30. De WH D, Olislagers V, Goriely S, et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004;103:1030-2.
31. Goriely S, Vincart B, Stordeur P, et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol 2001;166:2141-6.
32. Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999;162:5569-75.
33. Cherry JD, Feigin RD, Shockelford PG, et al. A clinical and serologic study of 103 children with measles vaccine failure. J Pediatr 1973;82:802-8.
34. Siegrist CA, Barrios C, Martinez X, et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol 1998;28:4138-48.
35. Berrington JE, Barge D, Fenton AC, et al. Lymphocyte subsets in term and significantly preterm UK infants in the first year of life analysed by single platform flow cytometry. Clin Exp Immunol 2005;140:289-92.
36. Bauer K, Zemlin M, Hummel M, et al. Diversification of Ig heavy chain genes in human preterm neonates prematurely exposed to environmental antigens. J Immunol 2002;169:1349-56.
37. Slack MH, Schapira D, Thwaites RJ, et al. Acellular pertussis vaccine given by accelerated schedule: response of preterm infants. Arch Dis Child Fetal Neonatal Ed 2004;89:F57-F60.
38. Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996;36:248-55.
39. Robinson MJ, Heal C, Gardener E, et al. Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who receive dexamethasone for chronic lung disease. Pediatrics 2004;113:733-7.
40. Robinson MJ, Campbell F, Powell P, et al. Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1999;80:F69-F71.
41. Clarke P, Robinson MJ, Powell PJ. DTP immunisation of steroid treated preterm infants. Arch Dis Child Fetal Neonatal Ed 2004;89:F468.
42. Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999;103:E14.
43. Munoz A, Salvador A, Brodsky NL, et al. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. Pediatrics 1995;96:216-19.
44. Clarke P, Robinson MJ, Ahmad I, et al. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine. Vaccine 2006;24(16):3273-8.
45. Slack MH, Schapira D, Thwaites RJ, et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis 2001;184:1617-20.
46. Pfister RE, Aeschbach V, Niksic-Stuber V, et al. Safety of DTaP-based combined immunization in very-low-birth-weight premature infants: frequent but mostly benign cardiorespiratory events. J Pediatr 2004;145:58-66.
47. Schulzke S, Heininger U, Lucking-Famira M, et al. Apnoea and bradycardia in preterm infants following immunisation with pentavalent or hexavalent vaccines. Eur J Pediatr 2005;164:432-5.
48. Sanchez PJ, Laptook AR, Fisher L, et al. Apnea after immunization of preterm infants. J Pediatr 1997;130:746-51.
49. Botham SJ, Isaacs D. Incidence of apnoea and bradycardia in preterm infants following triple antigen immunization. J Paediatr Child Health 1994;30:533-5.
50. Schloesser RL, Fischer D, Otto W, et al. Safety and immunogenicity of an acellular pertussis vaccine in premature infants. Pediatrics 1999;103:e60.
51. D'Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics 1995;96:18-22.
52. Khalak R, Pichichero ME, D'Angio CT. Three-year follow-up of vaccine response in extremely preterm infants. Pediatrics 1998;101:597-603.
53. Bonhoeffer J, Kohl K, Chen RT, et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 2004;22:547-50.
54. Omenaca F, Garcia-Sicilia J, Garcia-Corbeira P, et al. Response of preterm newborns to immunization with a hexavalent diphtheria-telanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 2005;116:1292-8.
55. Slack MH, Cade S, Schapira D, et al. DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation. Arch Dis Child 2005;90:338-41.
56. Linder N, Yaron M, Handsher R, et al. Early immunization with inactivated poliovirus vaccine in premature infants. J Pediatr 1995;127:128-30.
57. Adenyi-Jones SC, Faden H, et al. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 1992;120:686-9.
58. Kristensen K, Gyhrs A, Lausen B, et al. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J 1996;15:525-9.
59. Berrington JE, Cant AJ, Matthews JN, et al. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/ acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics 2006;117:e717-24.
60. Greenberg DP, Vadheim CM, Partridge S, et al. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group. J Infect Dis 1994; 170:76-81.
61. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984;149:1034-5.
62. Kayhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100.
63. Kirmani KI, Lofthus G, Pichichero ME, et al. Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics 2002;109:498-504.
64. Slack MH, Schapira D, Thwaites RJ, et al. Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal/Neonatal Ed 2004;89:F269-F71.
65. Lau YL, Tam AY, Ng KW, et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992;121:962-5.
66. Belloni C, Chirico G, Pistorio A, et al. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatr 1998;87:336-8.
67. Kesler K, Nasenbeny J, Wainwright R, et al. Immune responses of prematurely born infants to hepatitis B vaccination: results through three years of age. Pediatr Infect Dis J 1998;17:116-9.
68. Hepatitis B. In: Salisbury DM, Begg TM, eds. Immunisation against infectious disease (The green book). London: HMSO, 1996, chapter 18 (see new Hepatitis B chapter at http://www.dh.gov.uk/assetRoot/04/12/32/33/04123233.pdf, accessed 27 July 2006).
69. Collins CL, Ruggeberg JU, Balfour G, et al. Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants. Pediatr Infect Dis J 2005;24:966-8.
70. Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 2005;23:1703-8.
71. Rueggeberg J, Collins C, Clarke P, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine (PCV7) in preterm UK infants. Vaccine 2000 (in press).
72. Gans HA, Yasukawa LL, Alderson A, et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004;190:83-90.
73. Under N, Tallen-Gozani E, German B, et al. Placental transfer of measles antibodies: effect of gestational age and maternal vaccination status. Vaccine 2004;22:1509-14.
74. Leineweber B, Grote V, Schaad UB, et al. Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J 2004;23:361-3.
75. Groothuis JR, Levin MJ, Lehr MV, et al. Immune response to split-product influenza vaccine in preterm and full-term young children. Vaccine 1992;10:221-5.
76. Groothuis JR, Lehr MV, Levin MJ. Safety and immunogenicity of a purified haemogglutinin antigen in very young high-risk children. Vaccine 1994;12:139-41.
77. Booy R, Aitken SJ, Taylor S, et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 1992;339:507-10.
78. Department of Health UK. Planned changes to the routine Childhood Immunisation Programme, 8 February 2000. Gateway reference no: 6126, Available at http://www.dh.gov.uk/assetRoot/04/12/81/21/04128121.pdf (accessed 27 July 2006).
79. Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study. J Paediatr Child Health 1997;33:418-21.
80. Ellison VJ, Davis PG, Doyle LW. Adverse reactions to immunization with newer vaccines in the very preterm infant. J Paediatr Child Health 2005;41:441-3.
81. Pourcyrous M, Korones SB, Crouse D, et al. Interleukin-6, C-reactive protein, and abnormal cardiorespiratory responses to immunization in premature infants. Pediatrics 1998;101:E3.